Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis

Yoshikane Yamauchi, Yotaro Izumi, Masanori Inoue, Hiroaki Sugiura, Taichiro Goto, Masaki Anraku, Takashi Ohtsuka, Mitsutomo Kohno, Kenzo Soejima, Hiroaki Nomori

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors associated with the development and progression of IPF. The present study was done to evaluate the effects of administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection. Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3×10 5, 6×10 5, and 9×10 5 units/body/day, administered postoperatively for 3 days were evaluated. The endpoints were safety and feasibility. Results: Nine patients were evaluated, in cohorts of 3 patients per dosage. Postoperative follow up ranged from 3 to 12 months (median 9 months). The postoperative courses were uneventful in all patients. No subjective adverse events such as abdominal symptoms or skin rashes, or objective adverse events as per serum laboratory tests, such as liver or kidney dysfunctions potentially attributable to ulinastatin administration were observed. AE was seen in one patient at 3 months after surgery, but since this occurred shortly after administration of chemotherapy, it was considered to be attributable to the chemotherapy rather than surgery. Discussion: Ulinastatin administration after lung resection in lung cancer patients with IPF was considered to be safe and feasible. Further study is planned at the highest dose of this study to evaluate efficacy. Trial Registration: UMIN.ac.jp/ctr/UMIN000002410.

Original languageEnglish
Article numbere29053
JournalPLoS One
Volume6
Issue number12
DOIs
Publication statusPublished - 2011 Dec 22

Fingerprint

Idiopathic Pulmonary Fibrosis
trypsin inhibitors
lung neoplasms
fibrosis
Lung Neoplasms
lungs
Safety
resection
Chemotherapy
Surgery
dosage
Lung
drug therapy
surgery
Drug Therapy
Liver
urinastatin
Glycoproteins
Skin
Exanthema

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. / Yamauchi, Yoshikane; Izumi, Yotaro; Inoue, Masanori; Sugiura, Hiroaki; Goto, Taichiro; Anraku, Masaki; Ohtsuka, Takashi; Kohno, Mitsutomo; Soejima, Kenzo; Nomori, Hiroaki.

In: PLoS One, Vol. 6, No. 12, e29053, 22.12.2011.

Research output: Contribution to journalArticle

Yamauchi, Yoshikane ; Izumi, Yotaro ; Inoue, Masanori ; Sugiura, Hiroaki ; Goto, Taichiro ; Anraku, Masaki ; Ohtsuka, Takashi ; Kohno, Mitsutomo ; Soejima, Kenzo ; Nomori, Hiroaki. / Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. In: PLoS One. 2011 ; Vol. 6, No. 12.
@article{6a8086aa43c247ba9ae05cc2513a5fc1,
title = "Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis",
abstract = "Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors associated with the development and progression of IPF. The present study was done to evaluate the effects of administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection. Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3×10 5, 6×10 5, and 9×10 5 units/body/day, administered postoperatively for 3 days were evaluated. The endpoints were safety and feasibility. Results: Nine patients were evaluated, in cohorts of 3 patients per dosage. Postoperative follow up ranged from 3 to 12 months (median 9 months). The postoperative courses were uneventful in all patients. No subjective adverse events such as abdominal symptoms or skin rashes, or objective adverse events as per serum laboratory tests, such as liver or kidney dysfunctions potentially attributable to ulinastatin administration were observed. AE was seen in one patient at 3 months after surgery, but since this occurred shortly after administration of chemotherapy, it was considered to be attributable to the chemotherapy rather than surgery. Discussion: Ulinastatin administration after lung resection in lung cancer patients with IPF was considered to be safe and feasible. Further study is planned at the highest dose of this study to evaluate efficacy. Trial Registration: UMIN.ac.jp/ctr/UMIN000002410.",
author = "Yoshikane Yamauchi and Yotaro Izumi and Masanori Inoue and Hiroaki Sugiura and Taichiro Goto and Masaki Anraku and Takashi Ohtsuka and Mitsutomo Kohno and Kenzo Soejima and Hiroaki Nomori",
year = "2011",
month = "12",
day = "22",
doi = "10.1371/journal.pone.0029053",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis

AU - Yamauchi, Yoshikane

AU - Izumi, Yotaro

AU - Inoue, Masanori

AU - Sugiura, Hiroaki

AU - Goto, Taichiro

AU - Anraku, Masaki

AU - Ohtsuka, Takashi

AU - Kohno, Mitsutomo

AU - Soejima, Kenzo

AU - Nomori, Hiroaki

PY - 2011/12/22

Y1 - 2011/12/22

N2 - Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors associated with the development and progression of IPF. The present study was done to evaluate the effects of administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection. Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3×10 5, 6×10 5, and 9×10 5 units/body/day, administered postoperatively for 3 days were evaluated. The endpoints were safety and feasibility. Results: Nine patients were evaluated, in cohorts of 3 patients per dosage. Postoperative follow up ranged from 3 to 12 months (median 9 months). The postoperative courses were uneventful in all patients. No subjective adverse events such as abdominal symptoms or skin rashes, or objective adverse events as per serum laboratory tests, such as liver or kidney dysfunctions potentially attributable to ulinastatin administration were observed. AE was seen in one patient at 3 months after surgery, but since this occurred shortly after administration of chemotherapy, it was considered to be attributable to the chemotherapy rather than surgery. Discussion: Ulinastatin administration after lung resection in lung cancer patients with IPF was considered to be safe and feasible. Further study is planned at the highest dose of this study to evaluate efficacy. Trial Registration: UMIN.ac.jp/ctr/UMIN000002410.

AB - Background: Patients with idiopathic pulmonary fibrosis (IPF) undergoing pulmonary resection for lung cancer carry risks of acute exacerbations of IPF (AE) postoperatively. Currently, agents which may attenuate AE are actively sought. Urinary trypsin inhibitor, ulinastatin, is a synthetic glycoprotein which may potentially inhibit various inflammatory factors associated with the development and progression of IPF. The present study was done to evaluate the effects of administration of high dose ulinastatin in lung cancer patients with IPF immediately following lung resection. Methods: Patients with IPFs radiologically diagnosed on high resolution CT, and histologically diagnosed resectable lung cancers, were eligible for the study. The effects of escalating doses of ulinastatin 3×10 5, 6×10 5, and 9×10 5 units/body/day, administered postoperatively for 3 days were evaluated. The endpoints were safety and feasibility. Results: Nine patients were evaluated, in cohorts of 3 patients per dosage. Postoperative follow up ranged from 3 to 12 months (median 9 months). The postoperative courses were uneventful in all patients. No subjective adverse events such as abdominal symptoms or skin rashes, or objective adverse events as per serum laboratory tests, such as liver or kidney dysfunctions potentially attributable to ulinastatin administration were observed. AE was seen in one patient at 3 months after surgery, but since this occurred shortly after administration of chemotherapy, it was considered to be attributable to the chemotherapy rather than surgery. Discussion: Ulinastatin administration after lung resection in lung cancer patients with IPF was considered to be safe and feasible. Further study is planned at the highest dose of this study to evaluate efficacy. Trial Registration: UMIN.ac.jp/ctr/UMIN000002410.

UR - http://www.scopus.com/inward/record.url?scp=84055172763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84055172763&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0029053

DO - 10.1371/journal.pone.0029053

M3 - Article

C2 - 22216165

AN - SCOPUS:84055172763

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e29053

ER -